Industry News

• Valeant Pharmaceuticals completes divestiture of generic dermatology products to Mylan  valeant announced it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, an authorized generic of Efudex, to Mylan Inc.
  February 06, 2012  
• Neuralstem to raise $5.2 million in registered direct offering  Neuralstem announced that it has entered into agreements with certain institutional and accredited investors for a registered direct placement of 5,200,000 shares of common stock at a price of $1.00 per share for aggregate gross proceeds of $5,200,000.
  February 06, 2012  
• Fending off cardiovascular disease  A study of data from over a quarter of a million people confirmed that traditional risk factors for cardiovascular disease, such as high blood pressure, substantially raise the chance of major CVD events like heart attack or stroke over the course of a lifetime.
  February 06, 2012  
• CYTX awarded patents to treat wounds with stem cells  Cytori has been issued US Patent No. 8,105,580 covering methods of using adipose-derived stem and regenerative cells extracted by self-contained adipose tissue processing devices such as our Celution® System, to heal wounds, including non-healing diabetic wounds.
  February 06, 2012  
• Boston Scientific announces global launch of Expect™ 19 Flex endoscopic  Boston Scientific announced the global launch of the Expect 19 Flex Endoscopic Ultrasound Aspiration Needle, used for acquiring tissue samples under Endoscopic Ultrasound guidance for cancer diagnosis in organs adjacent to the gastrointestinal tract.
  February 06, 2012  
• Talon' product candidate Marqibo(R) to be assessed by Oncologic Drug Advisory Committee  Talon Therapeutics announced Marqibo® (vincristine sulfate liposomes injection) is scheduled to be assessed by ODAC March 21, 2012. Talon's NDA for Marqibo was accepted for filing by the FDA and is being reviewed under Accelerated Approval of New Drugs for Serious or Life Threatening Illnesses.
  February 03, 2012  
• Apricus Biosciences announces acquisition of NitroMist(TM) rights outside North America  Apricus announced an agreement with NovaDel Pharma for the sale and license of rights in territories outside of the U.S., Canada and Mexico to NovaDel's NitroMist®, an FDA-approved nitrate vasodilator indicated for acute relief of an attack or chest pain due to coronary artery disease.
  February 03, 2012  
• Transgenomic announces $22.0 million private placement   Transgenomic announced agreements with institutional and other accredited investors to raise $22.0 million in a private placement financing which includes an aggregate of $3.0 million in convertible notes issued in December to entities associated with Third Security, LLC.
  February 03, 2012  
• Gene regulator in brain's executive hub tracked across lifespan  For the first time, NIH scientists have tracked the activity, across the lifespan, of an environmentally responsive regulatory mechanism that turns genes on and off in the brain's executive hub.
  February 03, 2012  
• Depomed announces FDA approval of Merck's JANUMET(R) XR that accesses Depomed patents  Depomed announced that Merck's FDA approval of JANUMET® XR extended-release tablets, a new treatment for type 2 diabetes that combines sitagliptin, the active component of JANUVIA®. Depomed has provided Merck a license to patents directed to metformin extended release technology for JANUMET® XR.
  February 03, 2012  

   (next 10 articles)